KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Working Capital Changes (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Other Working Capital Changes data on record, last reported at -$27.5 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 220.35% year-over-year to -$27.5 million; the TTM value through Dec 2025 reached -$29.0 million, down 231.15%, while the annual FY2025 figure was -$29.0 million, 231.15% down from the prior year.
  • Other Working Capital Changes reached -$27.5 million in Q4 2025 per JAZZ's latest filing, down from -$6.3 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $127.6 million in Q4 2023 and bottomed at -$54.9 million in Q1 2024.
  • Average Other Working Capital Changes over 5 years is $6.1 million, with a median of $792000.0 recorded in 2025.
  • The widest YoY moves for Other Working Capital Changes: up 2415.0% in 2024, down 3094.39% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$18.8 million in 2021, then surged by 52.83% to -$8.9 million in 2022, then skyrocketed by 1539.89% to $127.6 million in 2023, then tumbled by 82.09% to $22.8 million in 2024, then plummeted by 220.35% to -$27.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$27.5 million in Q4 2025, -$6.3 million in Q3 2025, and $792000.0 in Q2 2025.